Evidence map›Paper›PMID 42395444›Full record

ArticlebioRxiv : the preprint server for biology2026

Orally available designed miniproteins inhibit enterotoxigenic

Pooja Srinivas, Victor Adebomi, Susan M Markiewicz, Kang Wang, Denise Chac, Kristofer Lindenauer, Nishoni Huber, Zhihang Tao, Phat Luong, Stephen A Rettie and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Pooja SrinivasDepartment of Microbial Pathogenesis and Microbial Sciences Institute, Yale University, New Haven, CT, USA.ORCID 0000-0001-7796-8827
Victor AdebomiDepartment of Medicinal Chemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-4573-5102
Susan M MarkiewiczDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID 0009-0002-9695-664X
Kang WangDepartment of Urology, Boston Children's Hospital, Boston, MA, USA.
Denise ChacDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-4183-3899
Kristofer LindenauerDepartment of Medicinal Chemistry, University of Washington, Seattle, WA, USA.
Nishoni HuberDepartment of Microbiology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-9827-4098
Zhihang TaoDepartment of Microbial Pathogenesis and Microbial Sciences Institute, Yale University, New Haven, CT, USA.ORCID 0009-0000-9720-519X
Phat LuongDepartment of Medicine, University of Washington, Seattle, WA, USA.
Stephen A RettieDepartment of Medicinal Chemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0001-9797-6939
Maisie W SmithDepartment of Microbial Pathogenesis and Microbial Sciences Institute, Yale University, New Haven, CT, USA.ORCID 0009-0001-3348-4254
Asim K BeraInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0000-0001-9473-2912
Alex KangInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0000-0001-5487-0499
Hannah NguyenInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Maika SchneiderDepartment of Medicinal Chemistry, University of Washington, Seattle, WA, USA.
Yaxi WangDepartment of Microbial Pathogenesis and Microbial Sciences Institute, Yale University, New Haven, CT, USA.
S Brook PetersonDepartment of Microbial Pathogenesis and Microbial Sciences Institute, Yale University, New Haven, CT, USA.
Min DongDepartment of Urology, Boston Children's Hospital, Boston, MA, USA.
Ana A WeilDepartment of Medicine, University of Washington, Seattle, WA, USA.
Gaurav BhardwajDepartment of Medicinal Chemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6170-4306
Joseph D MougousDepartment of Microbial Pathogenesis and Microbial Sciences Institute, Yale University, New Haven, CT, USA.ORCID 0000-0002-5417-4861

Funding

X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6M
Structure and Function of C. Difficile ToxinsR01AI139087 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Min Dong, Rongsheng Jin · 2018 to 2026
$7.4M
UW Post-Baccalaureate Research Education Program (PREP)R25GM086304 · NIGMS · UNIVERSITY OF WASHINGTON · PI Gabriele Varani · 2011 to 2026
$5.7M
Genome-wide CRISPR-Cas9 screens in insect cells to characterize insecticidal toxinsR01AI170835 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI DONG, MIN, PERRIMON, NORBERT · 2022 to 2025
$4.2M
Pixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0M
Molecular mechanism of tetanus neurotoxin pathogenesisR01AI189789 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Min Dong · 2025 to 2026
$1.6M
NIAID NIH HHS R01 AI139087NIAID NIH HHS R01 AI170835NIAID NIH HHS R01 AI189789NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R25 GM086304NIH HHS S10 OD021527
6 · The paper itself

Abstract

Toxigenic bacterial infections in the gut are a significant contributor to the global burden of disease. Advanced tools for protein and live biotherapeutic engineering offer potentially transformative strategies for treating such diseases, while avoiding the collateral effects of traditional antibacterials. Here we used de novo protein design to identify inhibitors of the metzincin family protease

Identifiers

PMID42395444
PMCPMC13320741

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.